Title 21, Food and DrugsRelease 119-110

§360g–1 Agency Documentation and Review of Significant Decisions Regarding Devices

Title 21 › CHAPTER 9 — FEDERAL FOOD, DRUG, AND COSMETIC ACT › SUBCHAPTER V — DRUGS AND DEVICES › Part A — Drugs and Devices › § 360g–1

Last updated Sep 22, 2026|Official source

Summary

The Secretary must give a clear, written summary explaining the scientific and regulatory reasons behind any important decision by the FDA’s Center for Devices and Radiological Health about certain device reports, classification petitions, applications, or exemption requests. The summary must note any major disagreements about the decision and say how those disagreements were resolved. If someone asks, the Secretary must give that summary to the person who is seeking to submit or who already submitted the report or application. The summary must also briefly explain how the “least burdensome” approach was considered and applied. Anyone affected can ask for a supervisory review of the decision. The request must be sent to the Secretary within 30 days of the decision and must say whether the person wants an in-person meeting or a teleconference. If asked, the Secretary must schedule the meeting or call within 30 days of the request and must issue a decision to the requester within 45 days of the request, or within 30 days after the meeting or call. These timing rules do not apply when the matter is sent to experts outside the FDA.

Full Legal Text

Title 21, §360g–1

Food and Drugs, Source: USLM XML via OLRC

(a)Documentation of rationale for significant decisions
(1)In general
The Secretary shall provide a substantive summary of the scientific and regulatory rationale for any significant decision of the Center for Devices and Radiological Health regarding submission or review of a report under section 360(k) of this title, a petition for classification under section 360c(f) of this title, an application under section 360e of this title, or an application for an exemption under section 360j(g) of this title, including documentation of significant controversies or differences of opinion and the resolution of such controversies or differences of opinion.
(2)Provision of documentation
Upon request, the Secretary shall furnish such substantive summary to the person who is seeking to submit, or who has submitted, such report or application.
(3)Application of least burdensome requirements
The substantive summary required under this subsection shall include a brief statement regarding how the least burdensome requirements were considered and applied consistent with section 360c(i)(1)(D) of this title, section 360c(a)(3)(D) of this title, and section 360e(c)(5) of this title, as applicable.
(b)Review of significant decisions
(1)Request for supervisory review of significant decision
Any person may request a supervisory review of the significant decision described in subsection (a)(1). Such review may be conducted at the next supervisory level or higher above the individual who made the significant decision.
(2)Submission of request
A person requesting a supervisory review under paragraph (1) shall submit such request to the Secretary not later than 30 days after such decision and shall indicate in the request whether such person seeks an in-person meeting or a teleconference review.
(3)Timeframe
(A)In general
Except as provided in subparagraph (B), the Secretary shall schedule an in-person or teleconference review, if so requested, not later than 30 days after such request is made. The Secretary shall issue a decision to the person requesting a review under this subsection not later than 45 days after the request is made under paragraph (1), or, in the case of a person who requests an in-person meeting or teleconference, 30 days after such meeting or teleconference.
(B)Exception
Subparagraph (A) shall not apply in cases that are referred to experts outside of the Food and Drug Administration.

Legislative History

Notes & Related Subsidiaries

Editorial Notes

Amendments

2022—Subsec. (a)(1). Pub. L. 117–328 amended par. (1) generally. Prior to amendment, text read as follows: “The Secretary shall provide a substantive summary of the scientific and regulatory rationale for any significant decision of the Center for Devices and Radiological Health regarding submission or review of a report under section 360(k) of this title, an application under section 360e of this title, a request for designation under section 360e–3 of this title, or an application for an exemption under section 360j(g) of this title, including documentation of significant controversies or differences of opinion and the resolution of such controversies or differences of opinion.” 2016—Subsec. (a)(1). Pub. L. 114–255, § 3051(b), inserted “a request for designation under section 360e–3 of this title,” after “application under section 360e of this title,”. Subsec. (a)(3). Pub. L. 114–255, § 3058(c), added par. (3).

Reference

Citations & Metadata

Citation

21 U.S.C. § 360g–1

Title 21, Food and Drugs

Last Updated

Sep 22, 2026

Release point: 119-110